PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1574934
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1574934
Tuberculosis Testing Market size was valued at USD 2,290.32 million in 2023, expanding at a CAGR of 5.99% from 2024 to 2032.
The tuberculosis (TB) testing market refers to the industry that provides various tests to diagnose TB, a serious infectious disease that mainly affects the lungs. This market includes different types of tests, such as skin tests, blood tests, and imaging tests like X-rays. The demand for TB testing has increased due to the rising number of TB cases worldwide and the need for early detection and treatment. Many organizations, including governments and health agencies, invest in TB testing to control the disease. Overall, the TB testing market plays a crucial role in public health by helping to identify and treat those affected by the disease.
Tuberculosis Testing Market- Market Dynamics
The increasing prevalence of drug-resistant tuberculosis strains drives testing demand.
The increasing prevalence of drug-resistant tuberculosis (TB) strains is a significant driver for the tuberculosis testing market. As these resistant strains become more common, timely and accurate testing is essential for effective treatment. According to the Centers for Disease Control and Prevention (CDC), about 3% of newly diagnosed TB cases in the U.S. are drug-resistant. This statistic highlights the urgent need for advanced testing solutions to identify and manage resistant strains effectively. Healthcare providers require reliable diagnostic tools to ensure appropriate treatment and control the spread of TB. As awareness grows, the demand for innovative testing methods will continue to rise, supporting market growth.
Tuberculosis Testing Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.99% over the forecast period (2024-2032)
Based on Test Type segmentation, Molecular diagnostics was predicted to show maximum market share in the year 2023
Based on End-user segmentation, Pathological laboratories was the leading type in 2023
Based on Region, North America was the leading revenue generator in 2023
The Global Tuberculosis Testing Market is segmented based on Test Type, End User, and Region.
The market is divided into Seven categories based on Test Type: Radiographic method, Diagnostic laboratory methods, Molecular diagnostics, Detection of latent infection, Cytokine detection assay, Detection of drug resistance (DST), Phage assay, and other test types. In the tuberculosis testing market, Molecular diagnostics, particularly the Polymerase Chain Reaction (PCR) method, is the most dominant segment. PCR is highly valued for its speed and accuracy in detecting Mycobacterium tuberculosis, even in small amounts of bacteria. This method allows for quick diagnosis, which is crucial for initiating timely treatment and controlling the spread of the disease. Its ability to identify drug resistance also enhances treatment options. As a result, PCR plays a key role in advancing tuberculosis diagnostics and improving patient outcomes.
The market is divided into categories based on End Users: Pathological laboratories, Point of care testing (POCT), and Others. In the tuberculosis testing market, pathological laboratories are the most important segment. These labs are essential for performing various tests, including culture methods and molecular diagnostics. They can handle many samples and provide accurate results, which is vital for diagnosing and managing TB. Their specialized equipment and trained staff ensure that complex tests are done correctly. As TB continues to be a major health issue, the role of pathological laboratories is crucial, making them the leading segment in the market.
Tuberculosis Testing Market- Geographical Insights
The North American tuberculosis testing market focuses on advanced diagnostic technologies. The United States and Canada are the leaders in this region, with significant investments in healthcare and research. In the U.S., the Centers for Disease Control and Prevention (CDC) promotes TB testing and prevention, raising awareness about the disease. There is a growing need for rapid testing methods, like molecular diagnostics, which help identify cases quickly. Government programs and funding also support testing, especially for high-risk groups. Major companies in the market drive innovation and make testing more accessible. Overall, North America plays an important role in improving tuberculosis testing and treatment efforts.
The tuberculosis testing market features a competitive landscape with several key players. Companies like Thermo Fisher Scientific and Roche lead in providing advanced diagnostic tools. Abbott Laboratories and BD offer a range of tests that help detect TB effectively. Cepheid is known for its rapid molecular testing solutions, which are becoming increasingly popular.
Hologic and QIAGEN also contribute innovative technologies to improve testing accuracy. Other notable players include BioMerieux and Oxford Immunotec, focusing on specialized testing methods. This diversity in offerings helps meet the growing demand for efficient tuberculosis diagnostics worldwide.
In November 2023, BD and Bio Farma signed a memorandum of understanding (MOU) to work together on addressing tuberculosis. BD offered access to its advanced TB diagnostic tools, while the partnership improved the supply chain for TB solutions in Indonesia.
In February 2023, Fisher Scientific launched real-time PCR kits in India for detecting various infectious diseases. These kits cover a range of conditions, including genetic analysis (HLA B27), Multi-Drug-Resistant Tuberculosis (MTB MDR), Hepatitis B Virus (HBV), M. Tuberculosis complex (MTB), Human Immunodeficiency Virus (HIV), and Hepatitis C Virus (HCV).